A small sensor clipped to a finger is about to do a bigger job. Masimo announced on October 17, 2026, from Irvine, California, via PR Newswire, that it has received FDA 510(k) clearance for an atrial fibrillation capability on its Radius VSM monitor, under the company’s smartSET platform. AFib, as clinicians shorten it, is an irregular heart rhythm that can be easy to miss between checks – and catching it earlier gives care teams something valuable: time to look closer.
The clearance matters because of where this kind of monitoring happens. Not only in intensive care, where patients are watched minute by minute, but on general care floors, where nurses cover many rooms and routine rounds come at intervals. Masimo’s stated aim is earlier evaluation on those floors, where deterioration can develop silently between routine rounds.
From single readings to patterns
Here is the shift, in plain terms. Traditional pulse oximetry gives a measurement – a number, at a moment. Masimo says smartSET extends that familiar tool from single measurements to pattern recognition, flagging physiological changes that are linked to clinical events. A single odd reading can be noise. A pattern is harder to dismiss.
The new AFib capability does not arrive alone. Masimo notes that smartSET already includes its previously cleared AI-enabled detection for opioid-induced respiratory depression, known as OIRD. Put the two together and the direction is clear: one platform, watching for more than one kind of trouble, using the signal from a sensor hospitals already know well.
That approach rhymes with other careful, checked uses of AI in medicine, including the growing investment in AI work where results can be verified. In a hospital, verification is not an academic nicety. It is the job.
Built on a long signal-processing record
Masimo built its name on getting a clean signal out of messy conditions. The company says the platform rests on its Signal Extraction Technology, known as SET, and on more than 35 years of signal-processing work. Motion, poor circulation, a patient who will not sit still – real wards are full of all three, and a monitor that cries wolf too often soon gets ignored. Accuracy under ordinary chaos is the whole game.
Dr. Basil Matta, the company’s Chief Medical Officer, framed the clearance as bringing AI-driven pattern recognition into the pulse oximetry workflow, so care teams can see subtle shifts earlier. That word, subtle, is the right one. The changes that precede trouble are often small at first. A system designed to notice small changes, and to surface them while there is still time to evaluate, addresses a real gap in floor care.
Why general care floors are the frontier
Ask any ward nurse where monitoring gets thin, and the answer is rarely the ICU. It is the general floor at 3 a.m., with a full assignment and patients who were stable at the last round. Between those rounds, a rhythm can change and no one is standing there to see it. Continuous monitoring that flags a pattern worth checking is built for exactly that stretch of the night.
It also sits comfortably alongside the week’s other encouraging medical news, including the first at-home thyroid eye treatment to win FDA approval. Different conditions, same theme: care moving closer to where patients actually are, with less delay built into the system.
There is a practical point here for hospital leaders, too. Adding a new capability to a monitor already in use is a different proposition from asking staff to learn an entirely new device in the middle of a shift. Radius VSM is the platform, smartSET is the software layer doing the pattern work, and this clearance widens what that combination can flag. Familiar hardware, broader watchfulness. For busy floors, that combination is not a minor detail. It is often the difference between a tool that gets adopted and one that stays in a supply room.
What happens next
Clearance is a beginning, not a finish line. A 510(k) clearance means the FDA has cleared the device capability for marketing, and hospitals will now make their own judgments, floor by floor, about how Radius VSM and smartSET fit their workflows, their staffing, and their patients. That evaluation process is normal, and it is healthy. Tools earn trust in use.
Masimo, a Danaher company, brings distribution and support muscle to that process, which matters more than outsiders might think. A monitor is not just a purchase. It is training, maintenance, and integration with the systems a hospital already runs. Scale helps with all of it.
For patients, the promise is refreshingly unglamorous. No grand claims, no magic. Just a familiar sensor, watched more intelligently, on the floors where a quiet change can otherwise go unnoticed for hours. If a flag from smartSET prompts one nurse to step into one room a little earlier and evaluate one patient a little sooner, the technology will have done precisely what Masimo says it was built to do.
Medicine advances this way more often than the headlines suggest – one clearance, one workflow, one earlier catch at a time. On October 17, in Irvine, it advanced again.
Be First to Comment